 The administration of estradiol halts, or reverses atrophic changes that occur due to the loss of endogenous estradiol during the menopause.Estrogen promotes endometrial cell growth and in postmenopausal women with an intact uterus, estrogen monotherapy results in continued endometrial development without the physiological secretory changes normally brought on by progesterone.This action is associated with an increased incidence of endometrial hyperplasia and carcinoma.